MNOV - MediciNova, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.76
-0.07 (-1.20%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.83
Open5.89
Bid0.00 x 1100
Ask0.00 x 1100
Day's Range5.76 - 5.97
52 Week Range5.58 - 13.37
Volume50,466
Avg. Volume97,709
Market Cap253.187M
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, ...

  • We're Not Worried About MediciNova's (NASDAQ:MNOV) Cash Burn
    Simply Wall St.

    We're Not Worried About MediciNova's (NASDAQ:MNOV) Cash Burn

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • Here is What Hedge Funds Think About MediciNova, Inc. (MNOV)
    Insider Monkey

    Here is What Hedge Funds Think About MediciNova, Inc. (MNOV)

    Is MediciNova, Inc. (NASDAQ:MNOV) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting […]

  • MNOV: Phase 3 Trial Initiated for MN-166 in ALS
    Zacks Small Cap Research

    MNOV: Phase 3 Trial Initiated for MN-166 in ALS

    By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT HERE Business Update Phase 3 Trial of MN-166 in ALS Underway In April 2019, MediciNova, Inc. (NASDAQ:MNOV) announced that following review of the protocol the U.S. Food and Drug Administration (FDA) determined that the company may proceed with the Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral

  • Does Market Volatility Impact MediciNova, Inc.'s (NASDAQ:MNOV) Share Price?
    Simply Wall St.

    Does Market Volatility Impact MediciNova, Inc.'s (NASDAQ:MNOV) Share Price?

    Anyone researching MediciNova, Inc. (NASDAQ:MNOV) might want to consider the historical volatility of the share price...

  • Zacks Small Cap Research

    MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium…

    On July 25, 2019, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2019. The increase was due to higher stock-based compensation offset by lower clinical trial expenses. As of July 24, 2019, MediciNova had approximately 43.2 million shares of common stock outstanding and when factoring in the approximately 6.8 million stock options a fully diluted share count of 50.1 million.

  • Zacks Small Cap Research

    MNOV: Readying for Phase 3 Trial in Multiple Sclerosis…

    The company is planning to conduct a single Phase 3 trial in patients with secondary progressive MS (SPMS) without relapses with the primary endpoint being the time to 3-month confirmed disability progression as measured by Expanded Disability Status Scale (EDSS). The EDSS is the ‘gold standard’ for assessing disability progression in patients with MS (Kurtzke, 1983).

  • What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)?
    Simply Wall St.

    What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)?

    If you want to know who really controls MediciNova, Inc. (NASDAQ:MNOV), then you'll have to look at the makeup of its...

  • Zacks Small Cap Research

    MNOV: Plans in Place for Phase 3 Trial in ALS…

    On April 15, 2019, MediciNova, Inc. (MNOV) announced that following review of the protocol the U.S. Food and Drug Administration (FDA) has determined that the company may proceed with the Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). If successful, results from this trial are expected to support a New Drug Application (NDA) for MN-166 in ALS. The Phase 2b/3 clinical trial will be a multi-center, two-arm, randomized, double blind, placebo controlled trial that will compare MN-166 to placebo in 150 patients with ALS.

  • If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today
    Simply Wall St.

    If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Buying shares in the best businesses can build meaningful wealth for you and your family. And we...

  • Benzinga

    The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...

  • Benzinga

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • Zacks Small Cap Research

    MNOV: New Analysis Shows Efficacy of MN-166 in Non-Relapsing SPMS…

    The SPRINT-MS trial was a Phase 2b clinical trial of patients with either secondary progressive MS (SPMS) or primary progressive MS (PPMS) in which participants received either MN-166 (100 mg/day) or placebo twice a day for a total of 96 weeks of treatment. The company has previously reported positive results from the SPRINT-MS trial, as it achieved both primary endpoints (a statistically significant 48% reduction in the rate of progression of whole brain atrophy along with safety and tolerability) and also demonstrated effects on important secondary endpoints including a positive trend of a 26% reduction in confirmed disability progression, which would be a primary endpoint in a Phase 3 trial.

  • Zacks Small Cap Research

    MNOV: Continuing to Plan for Phase 3 Studies in Progressive MS and ALS…

    MediciNova, Inc. (MNOV) is currently developing MN-166 (ibudilast) for a number of indications, with the lead programs being in progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The company has completed Phase 2 clinical trials with positive results from both trial trials. Progressive MS: Previously, the company had reported positive results from the SPRINT-MS Phase 2b clinical trial of MN-166 in patients with progressive MS.